Trials / Unknown
UnknownNCT03566472
The Blood Glucose Control in Patients With Type 2 Diabetes Treated With Glargine
The Current Situation and Influence Factors of Blood Glucose Control in Patients With Type 2 Diabetes Treated With Glargine in China
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 100 (estimated)
- Sponsor
- Nanjing First Hospital, Nanjing Medical University · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Glargine is commonly used in insulin supplemental therapy in patients with type 2 diabetes(T2D) at present. This study aims to investigate the current status of blood glucose control in patients with T2D treated with glargine. Glycated hemoglobin(HbA1c) will be tested in these patients to assess the blood glucose control and Continuous Glucose Monitoring System (CGMS) will be used to investigate the glucose variability. Islet function, duration of diabetes, complications, exercise, insulin dose, oral medication regimen and insulin antibodies will be recorded in detail. This study will analysis the association between these clinical characteristics and blood glucose control.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | Continuous Glucose Monitoring System | Continuous Glucose Monitoring System for 72 hours |
Timeline
- Start date
- 2018-06-12
- Primary completion
- 2018-12-30
- Completion
- 2019-07-31
- First posted
- 2018-06-25
- Last updated
- 2019-06-11
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03566472. Inclusion in this directory is not an endorsement.